Related Experiment Video
Updated: Feb 8, 2026

Author Spotlight: Advancing Metabolomics Analysis of Rare Hematopoietic Stem Cells
Published on: February 23, 2024
Rifaximin as a rare cause of rhabdomyolysis in cirrhosis
Alec B Rezigh1,2, Erin Armenia1,2, Ting Li1,2
1Internal Medicine Presbyterian St. Lukes Medical Center Denver CO USA.
Abstract:
Rifaximin has only been rarely reported to cause rhabdomyolysis. When physical and nonphysical etiologies have been excluded, thorough review of the patient's medication list is necessary. In cirrhotics, the potential harm of rifaximin in treatment or prophylaxis of hepatic encephalopathy should be recognized.
Insights
Rifaximin rarely causes rhabdomyolysis, a muscle-damaging condition. Always review patient medications, especially in cirrhotics, to identify potential drug-induced harm.
Area of Science:
- Pharmacology
- Hepatology
- Toxicology
Background:
- Rifaximin is a widely used antibiotic for hepatic encephalopathy.
- Rhabdomyolysis is a serious condition involving muscle breakdown.
Observation:
- This report details a rare case of rifaximin-induced rhabdomyolysis.
- Exclusion of other causes was critical in identifying the drug as the etiology.
Findings:
- Rhabdomyolysis is an infrequent adverse effect of rifaximin.
- Medication review is essential for diagnosing drug-induced conditions, particularly in patients with liver disease.
Implications:
- Clinicians should consider rifaximin as a potential cause of rhabdomyolysis.
- Careful patient monitoring and medication review are crucial in managing patients with cirrhosis and hepatic encephalopathy.
Related Concept Videos
Frequency-dependent Selection
Gene Evolution - Fast or Slow?
In contrast, regions which code...
Long-term Depression
Case Studies
Nondisjunction
Regression Toward the Mean

